Related Experiment Video
Updated: Sep 28, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Non-coding genome in small cell lung cancer between theoretical view and clinical applications
Xiaomeng Yin1, Jiqiao Yang2, Hang Wang3
1Department of Biotherapy, West China Hospital and State Key Laboratory of Biotherapy, Sichuan University, No. 37 GuoXue Alley, Chengdu 610041, China; West China School of Medicine, West China Hospital, Sichuan University, No. 37 GuoXue Alley, Chengdu 610041, China.
Abstract:
Small cell lung cancer (SCLC) is a highly aggressive cancer of the neuroendocrine system, characterized by poor differentiation, rapid growth, and poor overall survival (OS) of patients. Despite the recent advances in the treatment of SCLC recently, the 2-year survival rate of patients with the cancer is only 14-15%, occasioned by the acquired resistance to drugs and serious off-target effects. In humans, the coding region is only 2% of the total genome, and 20% of that is associated with human diseases. Beyond the coding genome are RNAs, promoters, enhancers, and other intricate elements. The non-coding regulatory regions, mainly the non-coding RNAs (ncRNAs), regulate numerous biological activities including cell proliferation, metastasis, and drug resistance. As such, they are potential diagnostic or prognostic biomarkers, and also potential therapeutic targets for SCLC. Therefore, understanding how non-coding elements regulate SCLC development and progression holds significant clinical implications. Herein, we summarized the recent discoveries on the relationship between the non-coding elements including long non-coding RNAs (lncRNA), microRNAs (miRNAs), circular RNA (circRNA), enhancers as well as promotors, and the pathogenesis of SCLC and their potential clinical applications.
Insights
Non-coding RNAs regulate small cell lung cancer (SCLC) progression and drug resistance. Understanding these non-coding elements offers potential diagnostic, prognostic, and therapeutic strategies for SCLC patients.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with poor patient survival rates.
- Current SCLC treatments face challenges due to drug resistance and off-target effects.
- The non-coding genome plays a crucial role in regulating biological processes and disease development.
Purpose of the Study:
- To review recent discoveries on non-coding elements in SCLC pathogenesis.
- To explore the clinical implications of non-coding RNAs (ncRNAs) in SCLC.
- To highlight the potential of ncRNAs as biomarkers and therapeutic targets for SCLC.
Main Methods:
- Literature review of recent research on non-coding elements and SCLC.
- Analysis of the roles of long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs).
- Examination of the involvement of enhancers and promoters in SCLC development.
Main Results:
- Non-coding elements, including lncRNAs, miRNAs, and circRNAs, significantly influence SCLC cell proliferation, metastasis, and drug resistance.
- Regulatory regions like enhancers and promoters are critical in SCLC pathogenesis.
- These non-coding elements demonstrate potential as diagnostic and prognostic biomarkers.
Conclusions:
- Non-coding RNAs are key regulators in SCLC development and progression.
- Targeting non-coding elements presents promising therapeutic strategies for SCLC.
- Further understanding of non-coding elements is crucial for advancing SCLC clinical applications.
